NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks. If, after doing this, organisations still wish to consider canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks, they should follow the advice set out in the Department of Health's 'Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance', which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.
NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.
For information about NICE guidance that has been issued or is in development, see the NICE website.
Febuxostat for the management of hyperuricaemia in people with gout. NICE technology appraisal guidance 164 (2008).